PE20230737A1 - Inhibidores de sarm1 - Google Patents

Inhibidores de sarm1

Info

Publication number
PE20230737A1
PE20230737A1 PE2023000530A PE2023000530A PE20230737A1 PE 20230737 A1 PE20230737 A1 PE 20230737A1 PE 2023000530 A PE2023000530 A PE 2023000530A PE 2023000530 A PE2023000530 A PE 2023000530A PE 20230737 A1 PE20230737 A1 PE 20230737A1
Authority
PE
Peru
Prior art keywords
alkyl
halogen
heteroaryl ring
cyano
sulfur
Prior art date
Application number
PE2023000530A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Simon Brearley
Rajesh Devraj
Robert Owen Hughes
Richard Andrew Jarjes-Pike
Shelley Anne Parrott
Todd Bosanac
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of PE20230737A1 publication Critical patent/PE20230737A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Pyridine Compounds (AREA)
PE2023000530A 2020-08-24 2021-08-23 Inhibidores de sarm1 PE20230737A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063069408P 2020-08-24 2020-08-24
US202163142398P 2021-01-27 2021-01-27
PCT/US2021/047093 WO2022046606A1 (en) 2020-08-24 2021-08-23 Inhibitors of sarm1

Publications (1)

Publication Number Publication Date
PE20230737A1 true PE20230737A1 (es) 2023-05-03

Family

ID=77775005

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000530A PE20230737A1 (es) 2020-08-24 2021-08-23 Inhibidores de sarm1

Country Status (22)

Country Link
US (2) US12043613B2 (enExample)
EP (1) EP4200293A1 (enExample)
JP (2) JP7349046B2 (enExample)
KR (2) KR20260016617A (enExample)
CN (1) CN122404291A (enExample)
AU (3) AU2021333558C1 (enExample)
BR (1) BR112023002575A2 (enExample)
CA (2) CA3313757A1 (enExample)
CL (1) CL2023000525A1 (enExample)
CO (1) CO2023001975A2 (enExample)
CR (1) CR20230113A (enExample)
DO (1) DOP2023000038A (enExample)
EC (1) ECSP23012981A (enExample)
IL (1) IL300586A (enExample)
JO (1) JOP20230037A1 (enExample)
MX (1) MX2023002256A (enExample)
NZ (1) NZ797733A (enExample)
PE (1) PE20230737A1 (enExample)
TW (3) TW202334117A (enExample)
UA (1) UA130657C2 (enExample)
WO (1) WO2022046606A1 (enExample)
ZA (1) ZA202301801B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3123215C (en) 2018-12-19 2024-04-02 Disarm Therapeutics, Inc. Inhibitors of sarm1 in combination with neuroprotective agents
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
WO2022060812A1 (en) 2020-09-16 2022-03-24 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
KR20240041987A (ko) 2021-07-28 2024-04-01 누라 바이오, 인크. Sarm1 억제제로서 치환된 피리딘 유도체
IL318437A (en) * 2022-07-21 2025-03-01 Amylyx Pharmaceuticals Inc Compositions containing oligonucleotides, and methods of using them
IL321043A (en) * 2022-12-15 2025-07-01 Sironax Ltd SARM1 modulators, their preparations and uses
WO2024158775A1 (en) 2023-01-24 2024-08-02 Disarm Therapeutics, Inc. Pyridazines as sarm1 inhibitors
CN121399112A (zh) * 2023-04-27 2026-01-23 维泰瑞隆有限公司 Sarm1调节剂、其制备和用途
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
WO2025049184A1 (en) 2023-08-25 2025-03-06 Eli Lilly And Company (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate
EP4766702A1 (en) * 2023-08-25 2026-07-01 F. Hoffmann-La Roche AG Pyrazole derivatives used as MRSA inhibitors useful for the treatment of neurodegenerative disorders
WO2025076088A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Lactams for use as sarm1 inhibitors
WO2025076017A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Carbamates for use as sarm1 inhibitors
TW202545928A (zh) 2024-01-25 2025-12-01 比利時商優稀美生物醫藥股份有限公司 吡咯啶酮衍生物
WO2026104394A1 (en) 2024-11-13 2026-05-21 UCB Biopharma SRL Pyrrolidinone derivatives inhibitors of sarm1

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11193281A (ja) 1997-10-27 1999-07-21 Takeda Chem Ind Ltd アデノシンa3受容体拮抗剤およびチアゾール化合物
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
AU2003288956A1 (en) 2002-10-30 2004-06-07 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
AU2003300099A1 (en) 2003-01-02 2004-07-29 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-Beta
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1751133B1 (en) 2004-04-28 2010-04-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
MX2007007330A (es) 2004-12-16 2007-10-04 Vertex Pharma Piridonas de utilidad como inhibidores de quinasas .
JP5244591B2 (ja) 2006-06-28 2013-07-24 あすか製薬株式会社 ピリジルイソオキサゾール誘導体
KR20090057032A (ko) 2006-09-21 2009-06-03 노파르티스 아게 사이토카인 매개 질환의 치료에 유용한 피롤 유도체
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Pi3キナーゼ阻害剤として用いられるチアゾール誘導体
WO2009080705A2 (en) 2007-12-20 2009-07-02 Novartis Ag Bis-thiazole derivatives, process for their preparation and their use as medicaments
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8785468B2 (en) 2009-02-13 2014-07-22 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
WO2012178022A2 (en) 2011-06-24 2012-12-27 University Of Massachusetts Therapeutic applications targeting sarm1
US9284310B2 (en) 2012-11-03 2016-03-15 Boehringer Ingelheim International Gmbh Inhibitors of cytomegalovirus
EP2934536B1 (en) 2012-12-19 2017-09-27 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
RU2570907C2 (ru) 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
WO2015084936A1 (en) 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
EP4091622A1 (en) 2016-08-16 2022-11-23 Henry Ford Health System Compositions for the treatment of chemotherapy-induced neuropathic pain
EP3515426A1 (en) 2016-09-24 2019-07-31 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
WO2018107056A1 (en) 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1,3-substitued pyrazole compounds useful for reduction of very long chain fatty acic levels
WO2018114663A1 (de) 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
BR112019012822A2 (pt) * 2016-12-22 2019-11-26 Bayer Ag 1,2,4-tiadiazolilpirrolonas e 1,2,4-tiadiazolil-hidantoínas e sais das mesmas e uso das mesmas como herbicidas
BR112020012651A2 (pt) 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos
EP3801503A4 (en) * 2018-06-07 2021-12-08 Disarm Therapeutics, Inc. INHIBITORS OF SARM1
CA3102645A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス, インコーポレイテッド Sarm1阻害剤
EP3919055A4 (en) 2019-01-30 2022-11-09 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND
US12624025B2 (en) 2019-06-06 2026-05-12 Disarm Therapeutics, Inc. Inhibitors of SARM1
JP7319395B2 (ja) 2019-06-14 2023-08-01 ディスアーム セラピューティクス, インコーポレイテッド Sarm1の阻害剤
KR20220035939A (ko) 2019-07-22 2022-03-22 바이엘 악티엔게젤샤프트 살충제로서의 5-아미노-치환된 피라졸 및 트리아졸
WO2021050913A1 (en) 2019-09-12 2021-03-18 Disarm Therapeutics, Inc. Inhibitors of sarm1
US20230029266A1 (en) 2019-11-05 2023-01-26 Dermira, Inc. MrgprX2 Antagonists for the Treatment of Inflammatory Disorders
AU2021206651B2 (en) 2020-01-07 2024-02-22 Disarm Therapeutics, Inc. Inhibitors of SARM1
WO2021207308A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Condensed pyrazole derivatives as inhibitors of sarm1
CA3174321A1 (en) 2020-04-09 2021-10-14 Disarm Therapeutics, Inc. Indazole derivatives as inhibitors of sarm1
EP4192828A1 (en) 2020-08-04 2023-06-14 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors

Also Published As

Publication number Publication date
AU2021333558A1 (en) 2023-03-02
TW202214597A (zh) 2022-04-16
TWI786777B (zh) 2022-12-11
KR20260016617A (ko) 2026-02-03
ECSP23012981A (es) 2023-03-31
TW202530197A (zh) 2025-08-01
US20220056013A1 (en) 2022-02-24
AU2021333558B2 (en) 2024-02-22
JOP20230037A1 (ar) 2023-02-23
DOP2023000038A (es) 2023-03-15
JP2023535236A (ja) 2023-08-16
CN122404291A (zh) 2026-07-17
MX2023002256A (es) 2023-03-17
AU2024203373A1 (en) 2024-06-13
TW202334117A (zh) 2023-09-01
ZA202301801B (en) 2024-09-25
AU2024203373B2 (en) 2026-04-02
US12043613B2 (en) 2024-07-23
BR112023002575A2 (pt) 2023-03-07
UA130657C2 (uk) 2026-04-08
CO2023001975A2 (es) 2023-03-07
IL300586A (en) 2023-04-01
KR102918550B1 (ko) 2026-01-27
EP4200293A1 (en) 2023-06-28
CL2023000525A1 (es) 2023-09-15
CR20230113A (es) 2023-04-14
CA3189181A1 (en) 2022-03-03
WO2022046606A1 (en) 2022-03-03
AU2026205227A1 (en) 2026-07-23
NZ797733A (en) 2026-03-27
JP7756130B2 (ja) 2025-10-17
AU2021333558C1 (en) 2024-06-20
US20240376083A1 (en) 2024-11-14
TWI904906B (zh) 2025-11-11
CA3313757A1 (en) 2026-06-21
JP7349046B2 (ja) 2023-09-21
JP2024016014A (ja) 2024-02-06
KR20230057396A (ko) 2023-04-28

Similar Documents

Publication Publication Date Title
ECSP055987A (es) Derivados de heteroarilcarbamoilbenceno
CL2020002423A1 (es) Nuevos compuestos heterocíclicos
CY1113099T1 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
AR069596A1 (es) Regulador del crecimiento de plantas
MX2017002241A (es) Compuestos de aminopirimidina como inhibidores de jak.
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
ATE556085T1 (de) Phosphoramiditverbindung und verfahren zur herstellung von oligo-rna
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
AR072166A1 (es) Derivado de piperidina y su uso como inhibidor de renina superior
CL2021000481A1 (es) Inhibidores de sarcómeros cardíacos.
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
CO2023004195A2 (es) Compuestos heterocíclicos
ECSP12012212A (es) Derivados de ariletinilo
PE20191020A1 (es) Compuestos quimicos
NO20084701L (no) Ny heterocyklisk forbindelse eller salt eller intermediat derav
WO2015104698A3 (en) Combination of novel nitrification inhibitors and biopesticides as well as combination of (thio)phosphoric acid triamides and biopesticides
AR049443A1 (es) Derivados de pirrolpiridinas
AR038703A1 (es) Derivados de 5-feniltiazol y uso como inhibidor de quinasa p i 3
CO2022000422A2 (es) Inhibidores de enzimas
PE20070243A1 (es) Compuestos heterociclicos como inhibidores de la transcriptasa reversa de vih
DOP2010000022A (es) Derivados de pirimidina 934
CO6180439A2 (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos
MX2020014087A (es) Moléculas inmunomoduladoras pequeñas novedosas.
AR074758A1 (es) Compuestos macrociclicos antivirales